Clinical trial
Efficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
NCT01766258 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
- Lead sponsor
- Orion Corporation, Orion Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- September 30, 2012
- Enrollment
- 117 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
parkinson's disease